Laser treatment of benign prostatic hyperplasia (BPH) reimbursed in Japan:
This article was originally published in Clinica
Sales of Trimedyne's lasers are expected to expand "significantly" now that the Japanese Ministry of Health and Welfare has approved reimbursement for the use of lasers to treat benign prostatic hyperplasia. Approved for marketing in Japan last year, the holmium laser is distributed in Japan by Meditec, a subsidiary of Marubeni. The reimbursement rate of $2,400 set by the Japanese Ministry includes hospital charges and the cost of the laser fibre.
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.